Ischemic tolerance in stroke treatment.
Although outcome after stroke treatment has significantly improved over the last 30 years, there has been no revolutionary breakthrough. Among different combined approaches, systemic thrombolysis in combination with neuroprotection became a favorite research target. Recent studies suggest that transient ischemic attacks may represent a clinical model of such ischemic tolerance; thus, a new focus on this research has emerged. In this review, we show the parallels between ischemia and neuroprotection and discuss the potential therapeutic options that may be opened by this new molecular knowledge.
Sandu
Nora
N
Department of Neurosurgery, University of Lausanne, Lausanne, Switzerland.
Cornelius
Jan
J
Filis
Andreas
A
Arasho
Belachew
B
Perez-Pinzon
Miguel
M
Schaller
Bernhard
B
D000818:Animals; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000503:physiopathology*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D020521:Stroke / Q000628:therapy*; D015912:Thrombolytic Therapy
D018696:Neuroprotective Agents